ERBB2 and breast cancer: Following the results of the phase II DESTINY-Breast01 and phase 3 DESTINY-Breast04 trials in BC patients, along with data from preclinical models [79] new combination strategies are being investigated, incorporating T-DXd and ICIs in HER2-expressing tumors.